The US Food and Drug Administration has approved Boehringer Ingelheim’s higher-concentration formulation of its Humira (adalimumab) biosimilar Cyltezo – but without granting it a coveted interchangeability designation, in an increasingly heated market.
While the company’s previously approved lower-concentration Cyltezo formulation was the first Humira biosimilar to receive the designation of interchangeability, the...